Capstone Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.12M | Sell |
18,442
-9,008
| -33% | -$525K | ﹤0.01% | 828 |
|
|
2025
Q4 | $1.48M | Sell |
27,450
-299,084
| -92% | -$14.4M | ﹤0.01% | 709 |
|
|
2025
Q3 | $14.7M | Buy |
326,534
+252,646
| +342% | +$11.8M | 0.03% | 253 |
|
|
2025
Q2 | $3.42M | Buy |
+73,888
| New | +$3.63M | 0.01% | 487 |
|
|
2025
Q1 | – | Sell |
-39,808
| Closed | -$2.32M | – | 1398 |
|
|
2024
Q4 | $2.25M | Sell |
39,808
-30,475
| -43% | -$1.7M | 0.01% | 813 |
|
|
2024
Q3 | $3.64M | Sell |
70,283
-153,996
| -69% | -$7.22M | 0.01% | 553 |
|
|
2024
Q2 | $9.31M | Buy |
224,279
+193,254
| +623% | +$8.65M | 0.03% | 323 |
|
|
2024
Q1 | $1.68M | Sell |
31,025
-321,271
| -91% | -$16.4M | 0.01% | 865 |
|
|
2023
Q4 | $18.1M | Buy |
352,296
+97,184
| +38% | +$5.1M | 0.05% | 227 |
|
|
2023
Q3 | $14.8M | Buy |
255,112
+81,437
| +47% | +$4.99M | 0.07% | 208 |
|
|
2023
Q2 | $11.1M | Buy |
173,675
+73,794
| +74% | +$4.95M | 0.05% | 233 |
|
|
2023
Q1 | $6.92M | Buy |
99,881
+93,396
| +1,440% | +$6.59M | 0.04% | 299 |
|
|
2022
Q4 | $467K | Buy |
6,485
+5,885
| +981% | +$444K | ﹤0.01% | 1150 |
|
|
2022
Q3 | $43K | Buy |
+600
| New | +$43.5K | ﹤0.01% | 1613 |
|
|
2022
Q1 | – | Sell |
-118,893
| Closed | -$7.98M | – | 2064 |
|
|
2021
Q4 | $7.41M | Sell |
118,893
-141,128
| -54% | -$8.28M | 0.01% | 706 |
|
|
2021
Q3 | $15.4M | Buy |
+260,021
| New | +$17.1M | 0.03% | 486 |
|
|
2021
Q1 | – | Sell |
-15,968
| Closed | -$993K | – | 1684 |
|
|
2020
Q4 | $990K | Buy |
+15,968
| New | +$982K | ﹤0.01% | 1083 |
|
|
2020
Q3 | – | Sell |
-6,353
| Closed | -$382K | – | 1390 |
|
|
2020
Q2 | $374K | Buy |
+6,353
| New | +$380K | ﹤0.01% | 1139 |
|
|
2020
Q1 | – | Sell |
-149
| Closed | -$9.11K | – | 1156 |
|
|
2019
Q4 | $10K | Buy |
+149
| New | +$8.53K | ﹤0.01% | 1356 |
|
|
2019
Q3 | – | Sell |
-8,549
| Closed | -$402K | – | 1354 |
|
|
2019
Q2 | $388K | Sell |
8,549
-9,222
| -52% | -$430K | ﹤0.01% | 1156 |
|
|
2019
Q1 | $848K | Sell |
17,771
-11,403
| -39% | -$568K | 0.01% | 866 |
|
|
2018
Q4 | $1.52M | Buy |
29,174
+14,255
| +96% | +$766K | 0.02% | 510 |
|
|
2018
Q3 | $926K | Buy |
14,919
+4,820
| +48% | +$286K | 0.01% | 622 |
|
|
2018
Q2 | $559K | Buy |
10,099
+7,646
| +312% | +$413K | 0.01% | 469 |
|
|
2018
Q1 | $155K | Buy |
+2,453
| New | +$158K | ﹤0.01% | 316 |
|
|
2017
Q2 | – | Sell |
-4,303
| Closed | -$233K | – | 650 |
|
|
2017
Q1 | $233K | Buy |
+4,303
| New | +$236K | 0.01% | 758 |
|
|
2014
Q4 | – | Sell |
-20,611
| Closed | -$1.05M | – | 336 |
|
|
2014
Q3 | $1.05M | Buy |
+20,611
| New | +$1.03M | 0.01% | 333 |
|
|
2014
Q2 | – | Sell |
-10,100
| Closed | -$524K | – | 406 |
|
|
2014
Q1 | $524K | Buy |
+10,100
| New | +$537K | 0.01% | 327 |
|
Other funds holding BMY
VCM
VPM
Capstone Investment Advisors's BMY Position: Q1 2026 in Review
Capstone Investment Advisors reduced its Bristol-Myers Squibb (BMY) stake by 33% in Q1 2026, selling an estimated $525K and leaving 18,442 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #828.
Capstone Investment Advisors first reported a position in BMY in Q1 2014 and has held it in 28 quarters since. The position peaked at $18.1M in Q4 2023. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Capstone Investment Advisors held 18,442 shares of Bristol-Myers Squibb worth $1.12M as of Q1 2026.
- Capstone Investment Advisors sold 9,008 Bristol-Myers Squibb shares in Q1 2026, an estimated $525K.
- Bristol-Myers Squibb made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #828 holding.
- Capstone Investment Advisors first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 28 quarters since.
- Capstone Investment Advisors's Bristol-Myers Squibb position peaked at $18.1M in Q4 2023.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.